MedTrace Logo

Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine

NCT05416476 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2024-02-28

No results posted yet for this study

Summary

In this study,288 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Anisodine Hydrobromide in preventing migraine attacks in episodic migraine in adults.

Conditions

  • Migraine Without Aura
  • Migraine With Aura

Interventions

DRUG

Anisodine Hydrobromide

Anisodine Hydrobromide 1 mg oral tablet, twice times a day

DRUG

Anisodine Hydrobromide placebo

Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Kaiming Liu, MD & PHD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2025-10-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05416476 on ClinicalTrials.gov